Log in
H

Hillhouse

HHLR Advisors · Investor
1Y performance ⓘ
−19%
AUM (13F)
$1.7B
# of Holdings
37
3Y performance ⓘ
+11%
vs S&P 500 ⓘ
−61%
Updated
Mar 31

Hillhouse's HHLR Advisors holds 37 U.S.-equity positions worth $1.7B (SEC 13F, Q1 2026). Top positions: Pdd Holdings Inc 25.4%, Alibaba Group Hldg Ltd 18.4%, Beone Medicines Ltd 18.4%. 13F-replication return is +11% over 3 years (-61 pts vs the S&P 500) — a replicated, non-audited figure.

Holdings

Stock% of portfolio SharesValue Latest activityAvg buy price Current priceDate
PDD Pdd Holdings Inc 25.4% 4.2M $426M ▼ 61% (−6.6M) $75.90 $78.11 (+3%) 2026-03-31
BABA Alibaba Group Hldg Ltd 18.4% 2.5M $308M ▼ 55% (−3.0M) $102.18 $104.97 (+3%) 2026-03-31
ONC Beone Medicines Ltd 18.4% 1.0M $307M $215.53 $271.80 (+26%) 2026-03-31
FUTU Futu Hldgs Ltd 11.6% 1.4M $194M ▼ 13% (−211K) $51.85 $99.97 (+93%) 2026-03-31
LEGN Legend Biotech Corp 6.5% 6.0M $108M $48.22 $29.34 (−39%) 2026-03-31
AVBP ArriVent BioPharma, Inc. Common Stock 5.4% 3.9M $91M $17.86 $32.70 (+83%) 2026-03-31
BEKE Ke Hldgs Inc 3.8% 4.2M $63M $18.84 $15.00 (−20%) 2026-03-31
CWAN Clearwater Analytics Holdings, Inc. 1.9% 1.4M $32M $21.93 $24.53 (+12%) 2026-03-31
CTKB Cytek Biosciences, Inc. Common Stock 1.7% 6.7M $29M $9.19 $3.86 (−58%) 2026-03-31
MRVL Marvell Technology, Inc. Common Stock 1.0% 171K $17M NEW (+171K) $70.88 $307.86 (+334%) 2026-03-31
YSG Yatsen Hldg Ltd 0.9% 4.9M $15M $2.11 $3.10 (+47%) 2026-03-31
NBP Novabridge Biosciences 0.9% 6.0M $15M $3.46 $1.53 (−56%) 2026-03-31
MAZE Maze Therapeutics, Inc. Common Stock 0.7% 366K $11M ▼ 20% (−92K) $11.01 $25.57 (+132%) 2026-03-31
CTNM Contineum Therapeutics, Inc. Class A Common Stock 0.5% 669K $9M $17.61 $11.62 (−34%) 2026-03-31
API Agora Inc 0.4% 2.1M $7M $4.16 $4.17 (+0%) 2026-03-31
BULL Webull Corporation Class A Ordinary Shares 0.4% 1.5M $7M ▼ 75% (−4.5M) $11.96 $6.86 (−43%) 2026-03-31
TSM Taiwan Semiconductor Manufac 0.3% 16K $5M ▲ 37% (+4K) $136.05 $467.67 (+244%) 2026-03-31
SGMT Sagimet Biosciences Inc. Series A Common Stock 0.2% 725K $4M $8.80 $7.10 (−19%) 2026-03-31
TUYA Tuya Inc 0.2% 1.6M $4M $1.89 $1.84 (−3%) 2026-03-31
GE GE Aerospace 0.2% 10K $3M $175.53 $355.12 (+102%) 2026-03-31
VIPS Vipshop Hldgs Ltd 0.1% 125K $2M NEW (+125K) $15.18 $13.24 (−13%) 2026-03-31
MOGU Mogu Inc 0.1% 848K $2M $3.25 $2.06 (−37%) 2026-03-31
GOSS Gossamer Bio, Inc. Common Stock 0.1% 5.0M $2M $1.26 $0.16 (−87%) 2026-03-31
INTC Intel Corp 0.1% 29K $1M NEW (+29K) $44.13 $140.94 (+219%) 2026-03-31
PACB Pacific Biosciences of California, Inc. 0.1% 919K $1M $8.35 $1.32 (−84%) 2026-03-31
EQX Equinox Gold Corp. 0.1% 80K $1M $11.22 $10.25 (−9%) 2026-03-31
NVDA NVIDIA CORP 0.1% 7K $1M NEW (+7K) $903.56 $208.65 (−77%) 2026-03-31
LITE Lumentum Holdings Inc. Common Stock 0.1% 2K $1M NEW (+2K) $702.76 $893.93 (+27%) 2026-03-31
GLW Corning Incorporated 0.1% 8K $1M NEW (+8K) $135.97 $209.83 (+54%) 2026-03-31
B Barrick Mining Corporation 0.1% 25K $1M $32.77 $40.14 (+22%) 2026-03-31
COHR Coherent Corp. 0.1% 4K $1M NEW (+4K) $238.21 $425.48 (+79%) 2026-03-31
DDL Dingdong Cayman Ltd 0.1% 354K $911K NEW (+354K) $2.57 $2.00 (−22%) 2026-03-31
AXIA Centrais Elet Bras Sa 0.0% 63K $712K ▼ 35% (−34K) $9.16 $10.31 (+13%) 2026-03-31
EWW Ishares Inc 0.0% 9K $662K NEW (+9K) $75.23 $75.96 (+1%) 2026-03-31
ALGS Aligos Therapeutics, Inc. Common Stock 0.0% 76K $567K $8.66 $5.69 (−34%) 2026-03-31
VNET Vnet Group Inc 0.0% 65K $546K ▲ 23% (+12K) $8.46 $8.55 (+1%) 2026-03-31
UXIN Uxin Ltd 0.0% 19K $59K $2.12 $1.71 (−19%) 2026-03-31
Related
PDD stockBABA stockONC stockFUTU stockAll hedge funds
FAQ

What are Hillhouse's largest holdings?

As of the latest 13F: Pdd Holdings Inc 25.4%, Alibaba Group Hldg Ltd 18.4%, Beone Medicines Ltd 18.4%, Futu Hldgs Ltd 11.6%, Legend Biotech Corp 6.5%.

How big is HHLR Advisors's 13F portfolio?

$1.7B across 37 disclosed U.S.-equity positions.

What is Hillhouse's 3-year performance?

+11% (13F-replication, price return), -61 pts vs the S&P 500. Not an audited fund return.

Where does this data come from?

U.S. SEC Form 13F-HR institutional holdings filings.

Sourced from SEC Form 13F-HR filings · Not investment advice
SEC EDGAR 13F
Data as of 2026-03-31 · Methodology
13F-replication (price return, filing-date based) — not an audited fund return.
Published by WealthFile · Not investment advice.

Latest activity = change vs. the prior 13F. Avg buy price = est. entry over the trailing 3 years (gain = vs. latest price). Returns are 13F-replication, not audited fund returns. Sourced from SEC 13F filings.